Mark Wong

Dr. Mark Wong is a Clinical Senior Lecturer in Medicine at the Westmead Clinical School, University of Sydney. His research focuses on cancer biomarkers, drug efficacy, and clinical trial design, particularly in oncology and pharmacology. He has contributed to studies on biomarkers for cholangiocarcinoma, radiation therapy alternatives for rectal cancer, and pharmacokinetic modeling of anti-cancer drugs like irinotecan and sunitinib. His work also includes optimizing tamoxifen dosing based on endoxifen levels and investigating immunotherapies for glioblastoma. Collaborations span global institutions, addressing challenges in drug metabolism and clinical trial methodologies. His research bridges basic science and translational medicine, aiming to improve patient outcomes through evidence-based strategies.

Key research interests include cancer pharmacology, therapeutic drug monitoring, and molecular targets in oncology. Notable projects involve evaluating prognostic biomarkers in liver cancers, exploring combination immunotherapies, and studying genetic factors influencing drug response in ovarian and colorectal cancers. His work frequently intersects with clinical practice, emphasizing practical applications in treatment optimization.

Publications highlight contributions to understanding drug resistance mechanisms, such as ABCB1 expression in ovarian cancer, and the predictive value of pharmacogenetic markers. Recent studies (2024) focus on preoperative biomarkers for biliary tract cancers, underscoring his ongoing dedication to improving diagnostic and therapeutic approaches in oncology.

Dr. Wong’s academic output reflects interdisciplinary collaboration, with articles spanning journals like Cancers, Lancet Oncology, and Clinical Cancer Research. While no awards are listed, his research has implications for advancing personalized cancer treatment strategies.